Polynovo Limited (AU:PNV)
ASX:PNV
Want to see AU:PNV full AI Analyst Report?
PNV Stock Chart & Stats
AU$1.01
AU$0.01(0.49%)
At close: 4:00 PM EST
AU$1.01
AU$0.01(0.49%)
Day’s Range― - ―
52-Week RangeAU$0.87 - AU$1.67
Previous CloseN/A
Volume733.50K
Average Volume (3M)1.48M
Market Cap
AU$666.66M
Enterprise ValueAU$845.35M
Total Cash (Recent Filing)AU$29.26M
Total Debt (Recent Filing)AU$31.74M
Price to Earnings (P/E)67.5
Beta1.67
Next Earnings
Aug 21, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume1,478,953
30 Day Avg. Volume1,476,427
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.56Price Target Upside54.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$150.68M
Bulls Say, Bears Say
Bulls Say
Revenue & U.S. Commercial MomentumConsistent double‑digit top‑line growth and rapid U.S. account expansion reflect durable commercial traction in hospital channels. A growing installed base of >800 accounts supports recurring, procedure‑linked revenues and increases clinical familiarity, easing future adoption and cross‑sell of new SKUs.
Exceptional Gross Margins & Improving ProfitabilityVery high gross margins indicate a scalable, low incremental cost product platform (NovoSorb) that can absorb commercial investment while preserving unit economics. Improved EBIT/EBITDA margins and positive adjusted EBITDA indicate operational leverage as sales scale, supporting sustainable long‑term cash generation potential if conversion improves.
Manufacturing Scale & Regulatory ProgressA validated facility with ~5x capacity materially reduces supply constraints and enables scale across multiple SKUs and geographies. Parallel PMA progress with BARDA strengthens regulatory positioning for on‑label indications, supporting broader hospital adoption and long‑term addressable market expansion once approvals are secured.
Bears Say
Weak Operating Cash ConversionFree cash flow deterioration and low operating cash conversion signal limited cash generated from reported earnings, constraining self‑funding of growth and capex. Continued improvement is required to finance scale, commercial expansion, and RCTs without dilutive capital raises or higher leverage over the medium term.
Outpatient Reimbursement UncertaintyOutpatient market upside depends on reproducible CMS coverage and pathway adoption. A required RCT for reimbursement creates a multiyear access hurdle, delaying material revenue conversion from outpatient channels and reducing visibility into the size and timing of a structurally larger, lower‑cost care segment.
Revenue Volatility & Limited GuidanceConcentration in episodic burn procedures leads to quarter‑to‑quarter volume swings, complicating operational planning and investment pacing. Management's refusal to provide formal guidance reflects underlying case variability, which hampers long‑term revenue visibility for planning large trials, scaling commercial operations, and managing working capital.
Polynovo News
PNV FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest share price was AU$0.86 and its highest was AU$1.67 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is AU$666.66M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Aug 21, 2026 which is in 66 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Feb 20, 2026. The company reported AU$0 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.006.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is 0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of AU$0 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -8.458%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in AU:PNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.56 (54.46% Upside)
AU$1.56 (54.46% Upside)
Blogger Sentiment
Bullish
AU:PNV Sentiment 97%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$140.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
11.87%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited is an innovative developer of medical devices, operating across key international markets including the United States, Australia, New Zealand, the United Kingdom, Ireland, and Singapore. The company's primary offering is the NovoSorb Biodegradable Temporising Matrix (BTM), a product engineered to facilitate the physiological closure of clean, surgically debrided wounds. Beyond this, PolyNovo is actively advancing a pipeline of new technologies, such as devices for hernia repair and tissue reinforcement, the NovoSorb Dermal Beta Cell Implant designed to house pancreatic islets within the skin, and various NovoSorb drug elution depots. Originally founded in 1998, the entity was known as Calzada Limited until it rebranded to PolyNovo Limited in November 2014. Its corporate headquarters are located in Port Melbourne, Australia.
PNV Company Deck
PNV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and commercial picture: double‑digit revenue growth across major regions (group +26%, U.S. +25.3%, RoW +28.3%), rapid MTX adoption (~+193%), improved cash flow (+$9.0M) and a strong clinical evidence base (348 studies). Key strategic catalysts (PMA submission, SynPath outpatient pathway, expanded manufacturing capacity, recruitment of a Chief Scientific Officer) provide clear upside. Short‑term headwinds include a timing‑related manufacturing variance (~$3.6–3.7M) from planned slowdowns, an R&D lab fire asset write‑off (insured), FX translation losses, and reimbursement/regulatory uncertainty for outpatient CMS coverage which may require an RCT. Management frames several negatives as one‑offs or timing issues and expects margin and free cash flow improvement in H2. Overall, highlights materially outweigh the lowlights.View all AU:PNV earnings summariesPNV Stock 12 Month Forecast
Average Price Target
AU$1.56
▲(54.46% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Options Prices
Currently, No data available
---